Tristel Share Discussion Threads

[mach100] 03/8/2020 18:04

Came on to post that the bounce was due to Byotrol. Augurs well though the buying fizzled out in the last hour.Will accumulate more as the share is good value now some froth has been wiped away.

[mw8156] 03/8/2020 14:45

byotrol update?

[gre] 03/8/2020 13:56

Anyone know why there is a big jump in share price over the last couple of hours? No big increase in shares being traded this morning. Has it just been tipped somewhere?

[piedro] 30/7/2020 08:43

Enjoy ...

Hygiene Theater Is a Huge Waste of Time
People are power scrubbing their way to a false sense of security.
JULY 27, 2020
Derek Thompson, Staff writer at The Atlantic

[q2u] 28/7/2020 10:42

My wife's private hospital has just started using Duo so what Tristel have lost in instrument disinfectant they are making up elswhere. The private healthcare market is a constant scrabble for profits despite their seemingly inflated prices so if they think this is worth the expense then there is not a lot to be worried about in my view.

[bbonsall] 25/7/2020 19:29

Thank you for that Piedro. It was very interesting and positive!

[piedro] 25/7/2020 08:30

The "IC webcast" ...

Investment Hour: Coronavirus update


- well worth a listen. {from 24 min.}

[james188] 24/7/2020 17:25

On the subject of share based payments, the concern is understandable and I thought that Phil Oakley made some valid points in the IC webcast today. That said, I personally don't have problem with senior management being rewarded well for growing the company significantly year on year and generating excellent shareholder total returns.

I first remember this issue coming to the fore for TSTL in early 2016, when the share price was around 110p.The complaint was that the 2015 LTIP was incorrectly calibrated and led to windfall gains. It had been 96p when the scheme was documented.

A revised scheme (the 2018 LTIP) was announced in November 2017 and set out in some detail at that time - options granted to senior management vested if the share price achieved 350p, 425p and 500p for a minimum three month period.There was a considerable amount of adverse comment at the time, but for all that, I was the only external shareholder who turned up for the 2017 AGM and asked the company about the arrangements. Responses were provided by David Orr (head of the Remuneration Committee) and Geoff Nash (company broker). I have not located my detailed notes, but I recall that I was told that a detailed comparison had been carried out with other bio companies - many of which were still loss making, unlike TSTL. The conclusion was that the proposed TSTL arrangements were fully in line and not towards the top end.

You can make the argument (as certain well known and respected commentators certainly have) that the product sells itself, irrespective of the quality of management. I do not share that view. I think that the company is at a potential inflection point and that senior management needs to be laser focused.The SBP are certainly an issue, but not the central one for me.

[apad] 24/7/2020 10:27

That point is covered in the interview.
apad

[11_percent] 24/7/2020 09:54

IC interview with Phil Oakley and some analyst comment......sorry if already posted.

Looks positive, with a build up of sales team in China.
This worries me a bit.......as we are protected by PIs.....which i would expect a China manufacturer to ignore.

[apad] 23/7/2020 11:10

Retesting today as well, bamboo2. I am looking to increase at 400 and change.
Appreciate your opinion - as you know I look at the graphs from a gut feel point of view 😊
apad

[bamboo2] 22/7/2020 22:05

Support just under 400 looks quite solid after the re-test today.

[mach100] 22/7/2020 21:53

James, Paul Barnes exercised 30000 but sold 350,000 worth of shares. The only tax bill he will be funding is from selling a huge chunk of shares!

They might even have been able to fund it (Paul Barnes partly)from these (albeit it was in the last tax year)

02-Mar-20 Sell Elizabeth Dixon 431.00 GBX 157,523 Holding 45,000
02-Mar-20 Buy Elizabeth Dixon 1.00 GBX 157,523 45,000
24-Feb-20 Sell Paul Martin Barnes 422.25 GBX 15,000 Holding 351,095

[james188] 22/7/2020 21:42

The director sales were largely to fund exercise/tax costs.I don't have an issue with that and I am much more interested in the long term trend of the share price and the company's prospects. I continue to believe that the company is still at a fairly early stage in its evolution. There are a lot of further opportunities that should be relatively easy to convert, both geographically and in product range.The fact that management is cautious is a plus point for me, but I hope (and expect)that they seize the present opportunities.

I have lots of questions (which I have set out today in an e-mail to the company),but I saw today as an obvious buy opportunity. The share price has always been volatile and I don't suppose that that will change within the foreseeable future.

[rob_evans] 22/7/2020 21:08

Quite a mixed bag today - good news as expected that disinfectants were up, to offset the drop in medical device decontamination.

The nasty shock for me was the news that FDA approval has been held up, with no timetable for when the process may resume. A big part of the attraction of the business was the prospect of breaking into the American market.

Unsurprisingly forward guidance was uncertain, as the Covid epidemic continues.

I think I'll continue to sit on the sidelines for now.

[mach100] 22/7/2020 20:14

22-Jul-20 Sell David Orr 404.20 GBX 15,000 43,191
22-Jul-20 Exercise of option David Orr 1.00 GBX 30,000 43,191
22-Jul-20 Exercise of option Paul Martin Barnes 1.00 GBX 30,000 30,000
22-Jul-20 Sell Paul Martin Barnes 404.20 GBX 351,095 30,000
22-Jul-20 Sell Elizabeth Dixon 404.20 GBX 198,198 178,334
22-Jul-20 Exercise of option Elizabeth Dixon 1.00 GBX 331,532 178,334
22-Jul-20 Sell Paul Christopher Swinney 404.20 GBX 320,431 643,095

Well that is the large trades cleared up. I know directors have limited windows to sell but these concerted sales really spook the market.

[paulisi] 22/7/2020 17:27

Excellent presentations and bear in mind that Europe and Australasia are the established and growing markets. China could be a huge market when they get established and South Asia and the Americas are areas which are awaiting government approval and could generate huge revenues in the next few years.

[deltaham] 22/7/2020 17:27

FYI: I cleared out my account balance and Bought 755 @ 410p at 12.17.02pm and remember the sell price at the time was about 406p. I note the large buy/sells at 12.17pm was @ 400p, 12.18pm was @ 404p and 12.19pm was @ 404p. So I'm confident the three large ones were all sells that in turn pulled the price down. The MMs now have loads of shares to sell back to us above £4.04 and still make a handsome profit. BTW I'm also a long term holder and very pleased and impressed with the presentation.

[mach100] 22/7/2020 14:08

Finn Cap have a target price of 460p in a note issued today. This would take us just under where we started the day. There will be some see-sawing around 425p I reckon as those that bought in at 400p might take profits while new investors come on board. Tony those trades actually look like buys given the prevailing price at the time so maybe a fund took advantage of the drop. I can declare in all honesty they were not my buys anyway.

[tonytyke2] 22/7/2020 13:20

Investors Chronicle just updated today after these results, with another BUY recommendation.

Anyone picking up 2 large sells? showing just after midday for nearly 1 million shares in total? Perhaps this could have influenced the share price today?

[hpcg] 22/7/2020 12:57

The backlog of invasive procedures required isn't going away, though there may perhaps be fewer interventions at the margin. The increase in customer experience is a bonus that could reap ongoing rewards.

[tonytyke2] 22/7/2020 11:27

Good presentations, well worth watching, I was also very impressed.

Very clear and detailed breakdown of all channels of income and you could see in June, that the medical device sales were starting to ramp up again. Overall international sales are really ramping up.

Hospitals have obviously increased the levels/frequency of surface cleaning and this is not going to go away.

[mach100] 22/7/2020 10:34

So the final dividend should be 4.2p at a minimum unless there is a severe reversal. 6.5p for the FY yielding over 1.5% currently. I don't expect it will stay at this price for long though and a move up to 450p again should be quite easily achievable.

[gre] 22/7/2020 10:07

I've just watched all of the online videos and am well impressed. The information given to shareholders is comprehensive and the details about the new Cache products is particularly impressive. Well done to all concerned.

This story has a long way to run and today's fall in the share price looks like a good buying opportunity.

[mach100] 22/7/2020 09:34

The presentation online looks good and will surely soothe investors fear. Cache has more than made up for the shortfall elsewhere. June saw a clear pick up in sales as hospital outpatient examinations return after the lockdown. share price recovering to an extent after bouncing off the low.